United Kingdom-based pharmaceutical and biotechnology company AstraZeneca announced on Sunday, that after conducting a review of those who received its coronavirus vaccine, it found no link between usage and an increased risk of blood clots. The company’s announcement comes as many countries have halted use of the vaccine, after Norway’s Medicines Agency announced cases of serious blood clotting following its use. The review by AstraZeneca included data more than 17 million people who had received the vaccine in the European Union and the UK. The country is expecting to receive an additional 8.6 millions doses of the AstraZeneca vaccine from COVAX, a global initiative aimed at providing developing countries with doses of the vaccine. IMAGE: Small bottles labeled with a “Vaccine COVID-19” sticker and a medical syringe are seen in this illustration taken April 10, 2020.

Source: Egypt Independent March 15, 2021 09:22 UTC